Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13913372 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4 | |
| SCHEMBL2880989 | 0.89 | ITGB1 (0.74) | ITGB1ITGA4 | |
| SCHEMBL5149425 | 0.88 | ITGB1 (0.44) | ITGB1ITGA4 | |
| SCHEMBL5147726 | 0.87 | ITGB1 (0.44) | ITGB1ITGA4 | |
| SCHEMBL6517864 | 0.86 | ITGB1 (0.63) | ITGB1ITGA4 | |
| SCHEMBL6508750 | 0.84 | ITGB1 (0.76) | ITGB1ITGA4 | |
| SCHEMBL7906165 | 0.82 | ITGB3 (0.52) | ITGB1 | |
| SCHEMBL14799578 | 0.82 | ITGB1 (0.56) | ITGB1ITGA4 | |
| SCHEMBL6561292 | 0.82 | ITGB1 (0.56) | ITGB1ITGA4 | |
| SCHEMBL13843664 | 0.82 | ITGB1 (0.60) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069376-A1 | VLA-4 Antagonists | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| US-20090069376-A1 | VLA-4 Antagonists | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| EP-1874299-A2 | VLA-4 ANTAGONISTS | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7291645-B2 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | disclosed |
| WO-2006115918-A2 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006115918-A2 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-7015216-B2 | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20040127486-A1 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ELAN PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| US-6689781-B2 | TREATING AN INFLAMMATORY CONDITION IN A MAMMALIAN PATIENT WHICH CONDITION IS MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2004-02-10 | — | — | US | disclosed |
| US-20020086882-A1 | Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-07-04 | — | — | US | disclosed |
| US-20020028812-A1 | Phenylalanine derivatives | CELLTECH CHIROSCIENCE LIMITED (GB) | 2002-03-07 | — | — | US | disclosed |
| US-6348463-B1 | Phenylalanine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086882-A1 | Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors | ITGAL, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885 |
| US-20020028812-A1 | Phenylalanine derivatives | PAH, FPR1, VCAM1 | ITGB1 4/4885ITGA4 32/4885 |
| US-20040127486-A1 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ITGB4, ITGA4, ITGB3 | ITGB1 5/4885ITGA4 2/4885 |
| US-20090069376-A1 | VLA-4 Antagonists | VCAM1, SELPLG, ITGB4 | ITGB1 15/4885ITGA4 4/4885 |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | ITGB1 3/4885ITGA4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.